Correlation between E-cadherin Expression and Prostate Cancer Risk in Chinese Population: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 CHENXiao-yan ¹ , WANGTing ¹ , TAOZhen-xia ¹ , ZENGXian-tao ^1,2,3 , LISheng ^1,2,3 ,  WENGHong ^1,2,3

1. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China;
2. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China;
3. Center for Evidence-Based and Translational Medicine, Wuhan University, Wuhan 430071, China;

Corresponding?author：

WENGHong, Email: wengh92@163.com

Keywords：

Prostate cancer; E-cadherin; Chinese people; Disease risk; Meta-analysis; Case-control study

DOI：

10.7507/1672-2531.20160121

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the correlation between E-cadherin expression and prostate cancer, as well as its clinicopathologic features in Chinese population. Methods Such databases as PubMed, EMbase, CBM, CNKI, VIP and WanFang Data were electronically searched from their inception to December, 2015 to collect case-control studies about the correlation between E-cadherin expression and prostate cancer, as well as its clinically pathologic features in Chinese population. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.3 software. Results A total of 21 studies were included, involving 920 prostate cancer cases, 415 benign prostatic hyperplasia cases, and 48 controls. The results of meta-analysis showed that the prostate cancer group had a lower E-cadherin expression level when compared with the benign prostatic hyperplasia group (OR=0.07, 95%CI 0.05 to 0.11, P<0.00001) or the control group (OR=0.04, 95%CI 0.01 to 0.18, P<0.00001). Moreover, the expression level of E-cadherin was lower in the low and medium differentiation group than in the high differentiation group (OR=0.13, 95%CI 0.08 to 0.23, P<0.00001), lower in the stage of C+D than in the stage of A+B (OR=0.23, 95%CI 0.15 to 0.34, P<0.00001), and lower in the prostate cancer with metastasis (OR=0.46, 95%CI 0.27 to 0.79, P=0.005) and it was decreased gradually with the increment of pathological differentiation and clinical stage of prostate cancer and with the decrement of lymph node or bone metastasis and serum PSA level. Conclusion Current evidence indicates that the expression level of E-cadherin is significantly correlated with prostate cancer and its clinicopathologic features in Chinese population. Due to limited sample size and quality of included studies, the conclusion needs to be verified by conducting more high quality studies.

Citation： CHENXiao-yan, WANGTing, TAOZhen-xia, ZENGXian-tao, LISheng, WENGHong. Correlation between E-cadherin Expression and Prostate Cancer Risk in Chinese Population: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2016, 16(7): 780-787. doi: 10.7507/1672-2531.20160121 Copy

1.	Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2):87-108.
2.	Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer:weighing the evidence. Eur Urol, 2013, 63(5):800-809.
3.	王行環, 瞿利軍. 前列腺癌早期診斷進展. 臨床外科雜志, 2006, 14(2):79-81.
4.	劉修恒. 前列腺癌的早期診斷. 臨床泌尿外科雜志, 2007, 22(7):482-485.
5.	Hodson R. Prostate cancer:4 big questions. Nature, 2015, 528(7582):S137.
6.	曾憲濤, 冷衛東, 郭毅, 等. Meta分析系列之一:Meta分析的類型. 中國循證心血管醫學雜志, 2012, 4(1):3-5.
7.	Li S, Kwong JS, Zeng XT, et al. Plasmakinetic resection technology for the treatment of benign prostatic hyperplasia:evidence from a systematic review and meta-analysis. Sci Rep, 2015, 5:12002.
8.	曾憲濤, 劉慧, 陳曦, 等. Meta分析系列之四:觀察性研究的質量評價工具. 中國循證心血管醫學雜志, 2012, 4(4):297-299.
9.	Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline:a systematic review. J Evid Based Med, 2015, 8(1):2-10.
10.	曾少波, 阮曉嵐, 翁鴻, 等. p63蛋白表達與非小細胞肺癌風險相關性的Meta分析. 湖北醫藥學院學報, 2015, 34(4):371-376.
11.	Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11):1539-1559.
12.	黃嘯, 周利群, 艾軍魁, 等. 前列腺癌E和N型鈣粘附素的表達及意義. 癌癥, 2002, 21(11):1208-1211.
13.	戚曉平, 錢斌, 林考興, 等. 前列腺癌組織中ILK和E-Cadherin的表達及其意義. 實用癌癥雜志, 2004, 19(5):478-480.
14.	姚青, 穆紅, 張建民, 等. 前列腺病變中E-cadherin、p16和ER表達及意義. 臨床與實驗病理學雜志, 2004, 20(6):698-701.
15.	谷化平, 尚培中, 周翠玲. CD44v6和E-上皮鈣黏附素在前列腺癌組織中的表達與癌轉移的關系. 中華男科學雜志, 2004, 10(1):32-34.
16.	閻利, 戚曉平, 林孝興, 等. E-cadherin蛋白在前列腺癌組織中的表達及臨床意義. 臨床軍醫雜志, 2004, 23(2):32-34.
17.	何全中. COX-2和E-cadherin在前列腺癌中的表達與意義. 新鄉:新鄉醫學院, 2006.
18.	張錫流, 何仕遠, 張力, 等. E-鈣黏附蛋白及其相關蛋白在前列腺癌組織中的表達及其臨床意義. 檢驗醫學, 2006, 21(1):5-7.
19.	朱煊. 前列腺癌中E鈣粘連蛋白和環氧化酶2表達的免疫組化研究. 長沙:中南大學, 2007.
20.	孫明, 潘春雨, 劉學鋒, 等. S100A4蛋白和E-cadherin蛋白在前列腺癌中的表達及臨床意義. 現代腫瘤醫學, 2009, 17(10):1921-1924.
21.	侯鑄, 羅勇, 趙佳暉, 等. EMT標記蛋白在前列腺癌組織中的表達及其意義. 中國男科學雜志, 2009, 23(12):21-24.
22.	王霞, 章明放, 張玉潔. 鈣黏附蛋白及降鈣素在前列腺癌組織中的表達及意義. 山東醫藥, 2010, 50(43):34-36.
23.	高雙友, 宋蕊, 李雙利, 等. E-cadherin及sE-cadherin在42例前列腺癌中的表達及意義. 重慶醫學, 2010, 39(23):3240-3241.
24.	冀楠. Snail、Slug、E-cadherin在前列腺癌中的表達及其意義. 武漢:武漢科技大學, 2011.
25.	毛洲洲. Survivin和E-Cadherin在前列腺癌中的表達及意義. 湛江:廣東醫學院, 2011.
26.	胡祥坤, 程帆, 阮遠, 等. p130Cas和E-cadherin在前列腺癌組織中的表達及其臨床意義. 中華實驗外科雜志, 2011, 28(12):2055-2056.
27.	姜濤, 姜輝, 蘇曉明, 等. E-cd和α-Cat表達與前深腺組織良惡性和轉移性關系的研究. 中華男科學雜志, 2012, 18(6):499-503.
28.	王翔. E-cadherin、TGF-β1及Twist在前列腺癌中的表達及意義. 濟南:山東大學, 2013.
29.	溫爽, 蓋宇, 宗華鳳, 等. 前列腺癌組織P504S、E-Cadherin和bcl-2蛋白表達及意義. 大連醫科大學學報, 2013, 35(2):25-28.
30.	郭宏濤. E-cadherin和N-cadherin在前列腺癌中的表達及意義. 蘭州:蘭州大學, 2014.
31.	劉祎, 陳先國, 梁朝朝. 前列腺癌腫瘤組織中E-cadherin和N-cadherin的表達及意義. 中華男科學雜志, 2014, 20(9):781-786.
32.	韓麗媛, 王偉, 王慧萍, 等. 前列腺癌組織中p53、bcl-2和E-cadherin蛋白的表達水平及臨床意義. 生殖醫學雜志, 2015, 24(10):845-849.
33.	Masterson J, O'Dea S. Posttranslational truncation of E-cadherin and significance for tumour progression. Cells Tissues Organs, 2007, 185(1-3):175-179.
34.	Halbleib JM, Nelson WJ. Cadherins in development:cell adhesion, sorting, and tissue morphogenesis. Genes Dev, 2006, 20(23):3199-3214.
35.	石珍亮, 張遜. E-cadherin黏附系統及其與腫瘤侵襲轉移的關系. 天津醫藥, 2008, 36(6):476-478.
36.	Gould RB, Bracken MB. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast:a systematic review and meta-analysis. Breast Cancer Res Treat, 2006, 100(2):139-148.
37.	那彥群, 葉章群, 孫穎浩, 等. 中國臨床泌尿外科疾病診斷治療指南. 北京:人民衛生出版社, 2013.

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2):87-108.
2. Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer:weighing the evidence. Eur Urol, 2013, 63(5):800-809.
3. 王行環, 瞿利軍. 前列腺癌早期診斷進展. 臨床外科雜志, 2006, 14(2):79-81.
4. 劉修恒. 前列腺癌的早期診斷. 臨床泌尿外科雜志, 2007, 22(7):482-485.
5. Hodson R. Prostate cancer:4 big questions. Nature, 2015, 528(7582):S137.
6. 曾憲濤, 冷衛東, 郭毅, 等. Meta分析系列之一:Meta分析的類型. 中國循證心血管醫學雜志, 2012, 4(1):3-5.
7. Li S, Kwong JS, Zeng XT, et al. Plasmakinetic resection technology for the treatment of benign prostatic hyperplasia:evidence from a systematic review and meta-analysis. Sci Rep, 2015, 5:12002.
8. 曾憲濤, 劉慧, 陳曦, 等. Meta分析系列之四:觀察性研究的質量評價工具. 中國循證心血管醫學雜志, 2012, 4(4):297-299.
9. Zeng X, Zhang Y, Kwong JS, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline:a systematic review. J Evid Based Med, 2015, 8(1):2-10.
10. 曾少波, 阮曉嵐, 翁鴻, 等. p63蛋白表達與非小細胞肺癌風險相關性的Meta分析. 湖北醫藥學院學報, 2015, 34(4):371-376.
11. Higgins J, Thompson S. Quantifying heterogeneity in a meta-analysis. Stat Med, 2002, 21(11):1539-1559.
12. 黃嘯, 周利群, 艾軍魁, 等. 前列腺癌E和N型鈣粘附素的表達及意義. 癌癥, 2002, 21(11):1208-1211.
13. 戚曉平, 錢斌, 林考興, 等. 前列腺癌組織中ILK和E-Cadherin的表達及其意義. 實用癌癥雜志, 2004, 19(5):478-480.
14. 姚青, 穆紅, 張建民, 等. 前列腺病變中E-cadherin、p16和ER表達及意義. 臨床與實驗病理學雜志, 2004, 20(6):698-701.
15. 谷化平, 尚培中, 周翠玲. CD44v6和E-上皮鈣黏附素在前列腺癌組織中的表達與癌轉移的關系. 中華男科學雜志, 2004, 10(1):32-34.
16. 閻利, 戚曉平, 林孝興, 等. E-cadherin蛋白在前列腺癌組織中的表達及臨床意義. 臨床軍醫雜志, 2004, 23(2):32-34.
17. 何全中. COX-2和E-cadherin在前列腺癌中的表達與意義. 新鄉:新鄉醫學院, 2006.
18. 張錫流, 何仕遠, 張力, 等. E-鈣黏附蛋白及其相關蛋白在前列腺癌組織中的表達及其臨床意義. 檢驗醫學, 2006, 21(1):5-7.
19. 朱煊. 前列腺癌中E鈣粘連蛋白和環氧化酶2表達的免疫組化研究. 長沙:中南大學, 2007.
20. 孫明, 潘春雨, 劉學鋒, 等. S100A4蛋白和E-cadherin蛋白在前列腺癌中的表達及臨床意義. 現代腫瘤醫學, 2009, 17(10):1921-1924.
21. 侯鑄, 羅勇, 趙佳暉, 等. EMT標記蛋白在前列腺癌組織中的表達及其意義. 中國男科學雜志, 2009, 23(12):21-24.
22. 王霞, 章明放, 張玉潔. 鈣黏附蛋白及降鈣素在前列腺癌組織中的表達及意義. 山東醫藥, 2010, 50(43):34-36.
23. 高雙友, 宋蕊, 李雙利, 等. E-cadherin及sE-cadherin在42例前列腺癌中的表達及意義. 重慶醫學, 2010, 39(23):3240-3241.
24. 冀楠. Snail、Slug、E-cadherin在前列腺癌中的表達及其意義. 武漢:武漢科技大學, 2011.
25. 毛洲洲. Survivin和E-Cadherin在前列腺癌中的表達及意義. 湛江:廣東醫學院, 2011.
26. 胡祥坤, 程帆, 阮遠, 等. p130Cas和E-cadherin在前列腺癌組織中的表達及其臨床意義. 中華實驗外科雜志, 2011, 28(12):2055-2056.
27. 姜濤, 姜輝, 蘇曉明, 等. E-cd和α-Cat表達與前深腺組織良惡性和轉移性關系的研究. 中華男科學雜志, 2012, 18(6):499-503.
28. 王翔. E-cadherin、TGF-β1及Twist在前列腺癌中的表達及意義. 濟南:山東大學, 2013.
29. 溫爽, 蓋宇, 宗華鳳, 等. 前列腺癌組織P504S、E-Cadherin和bcl-2蛋白表達及意義. 大連醫科大學學報, 2013, 35(2):25-28.
30. 郭宏濤. E-cadherin和N-cadherin在前列腺癌中的表達及意義. 蘭州:蘭州大學, 2014.
31. 劉祎, 陳先國, 梁朝朝. 前列腺癌腫瘤組織中E-cadherin和N-cadherin的表達及意義. 中華男科學雜志, 2014, 20(9):781-786.
32. 韓麗媛, 王偉, 王慧萍, 等. 前列腺癌組織中p53、bcl-2和E-cadherin蛋白的表達水平及臨床意義. 生殖醫學雜志, 2015, 24(10):845-849.
33. Masterson J, O'Dea S. Posttranslational truncation of E-cadherin and significance for tumour progression. Cells Tissues Organs, 2007, 185(1-3):175-179.
34. Halbleib JM, Nelson WJ. Cadherins in development:cell adhesion, sorting, and tissue morphogenesis. Genes Dev, 2006, 20(23):3199-3214.
35. 石珍亮, 張遜. E-cadherin黏附系統及其與腫瘤侵襲轉移的關系. 天津醫藥, 2008, 36(6):476-478.
36. Gould RB, Bracken MB. E-cadherin immunohistochemical expression as a prognostic factor in infiltrating ductal carcinoma of the breast:a systematic review and meta-analysis. Breast Cancer Res Treat, 2006, 100(2):139-148.
37. 那彥群, 葉章群, 孫穎浩, 等. 中國臨床泌尿外科疾病診斷治療指南. 北京:人民衛生出版社, 2013.

Chinese Journal of Evidence-Based Medicine

Correlation between E-cadherin Expression and Prostate Cancer Risk in Chinese Population: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content